**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 57645

**Manuscript Type:** SYSTEMATIC REVIEWS

**Insufficient etiological workup of COVID-19-associated acute pancreatitis: A systematic review**

Juhász MF *et al.* Insufficient etiological workup/COVID-19-associated pancreatitis

Márk Félix Juhász, Klementina Ocskay, Szabolcs Kiss, Péter Hegyi, Andrea Párniczky

**Márk Félix Juhász, Klementina Ocskay,** Institute for Translational Medicine, University of Pécs, Medical School, Pécs 7624, Hungary

**Szabolcs Kiss,** Doctoral School of Clinical Medicine, University of Szeged, Szeged 6720, Hungary

**Péter Hegyi,** Institute for Translational Medicine, Medical School, University of Pécs, Pécs 7624, Hungary

**Andrea Párniczky,** Department of Pediatrics, Heim Pál National Institute for Pediatrics, Budapest 1089, Hungary

**Author contributions:** Juhász MF and Ocskay K contributed equally, as first authors, in the systematic search and selection, data extraction, writing, preparing tables and figures; Kiss S performed the risk of bias assessment and prepared one of the tables; Hegyi P provided critical insight for the focus and writing of the article; Párniczky A contributed to the design and coordinated the writing of the paper.

**Supported by** European Union (European Regional Development Fund), No. GINOP-2.3.2-15-2016-00048 and EFOP 3.6.2-16-2017-00006.

**Corresponding author: Andrea Párniczky, MD, PhD, Doctor, Research Fellow,** Department of Pediatrics, Heim Pál National Institute for Pediatrics, Üllői Street 86, Budapest 1089, Hungary. andrea.parniczky@gmail.com

**Received:** June 17, 2020

**Revised:** August 11, 2020

**Accepted:** September 23, 2020

**Published online:** October 28, 2020

**Abstract**

BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, mostly causing respiratory symptoms, is also known to affect the gastrointestinal tract. Several case reports hypothesize that SARS-CoV-2 could be an etiological factor in acute pancreatitis (AP).

AIM

To assess all the available evidence in the literature relating to coronavirus disease 2019 (COVID-19) and AP.

METHODS

We performed a systematic review of the available literature on the topic. The systematic search was conducted on 15 May 2020 on MEDLINE, Embase, CENTRAL, Web of Science and Scopus with a search key using the terms “amylase,” “lipase,” “pancr\*,” “COVID-19” and synonyms. Due to the low quality and poor comparability of the studies, a meta-analysis was not performed.

RESULTS

Six case reports and two retrospective cohorts were included, containing data on eleven COVID-19 patients with AP. Five patients had AP according to the Atlanta classification. Other publications did not provide sufficient information on the diagnostic criteria. Most cases were considered SARS-CoV-2-induced, while several established etiological factors were not investigated. We were able to identify other possible causes in most of them.

CONCLUSION

We strongly highlight the need for adherence to the guidelines during a diagnostic and etiological workup, which could alter therapy.

**Key Words:** Pancreas; COVID-19; Pancreatic involvement; Pancreatitis; Amylase; Lipase

**Citation:** Juhász MF, Ocskay K, Kiss S, Hegyi P, Párniczky A. Insufficient etiological workup of COVID-19-associated acute pancreatitis: A systematic review. *World J Gastroenterol* 2020; 26(40): 6270-6278

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i40/6270.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i40.6270

**Core Tip:** As the severe acute respiratory syndrome coronavirus 2 pandemic spreads, numerous coronavirus disease 2019 patients will be diagnosed with acute pancreatitis (AP). Viral infections are known etiological factors of AP, but taking a look at the available literature several shortcomings of the diagnostic end etiological workups were uncovered, therefore the causative relationship between coronavirus disease 2019 and AP cannot be established. We highlight the fundamental role of guideline adherence in the diagnosis and etiological workup of AP since etiology-specific therapeutic options are available. Identifying underlying etiological factors is the foundation of high-quality patient care in AP.

**INTRODUCTION**

In 2019, a novel coronavirus emerged in Wuhan, China, causing multiple cases of severe pneumonia and launching the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The clinical syndrome seen in SARS-CoV-2 infection is called coronavirus disease 2019 (COVID-19). The main clinical symptoms of COVID-19 are fever, cough, myalgia, and fatigue[1]. Pulmonary involvement is the most frequent[2], but systemic dissociation is seen in severe cases. Furthermore, a significant proportion of patients exhibit gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain. SARS-CoV-2 was also detected in stool specimens[3] and in the cytoplasm of gastric, duodenal, and rectal glandular epithelial cells[4].

Viral infections such as mumps, Coxsackie, hepatitis, and herpes viruses are known causes of pancreatitis[5]. There is a strong possibility that, like other, less common causes of acute pancreatitis (AP), infectious etiology is underdiagnosed on account of the insufficient workup of idiopathic cases and cases where an apparent cause (*e.g.,* alcohol consumption) is already established[6-8].

On the other hand, during a pandemic of such proportions, polymerase chain reaction testing is made widely available. This will of course lead to a proportion of patients with a variety of diseases, including AP, being diagnosed with SARS-CoV-2 infection. Given the right temporal association, even a more experienced practitioner could be led to ponder a cause-effect relationship between COVID-19 and AP. Even more so, taking into account the often-neglected etiological workup of idiopathic cases and the opportunity to aid the scientific and medical communities by providing information on presumed complications of the infection.

This systematic review aims to assess all publications containing COVID-19 AP cases and to determine the plausibility of an association between the two.

**MATERIALS AND METHODS**

***Protocol and registration***

This systematic review was registered with PROSPERO as “Pancreas involvement in COVID-19: A systematic review” under registration number CRD42020186426. After completing the systematic search, we decided to deviate from the protocol for the eligibility of studies: we narrowed our focus to AP from the original plan of any pancreatic involvement. We did so because slight pancreatic enzyme elevation in COVID-19 patients, reported by two studies[9,10], has already been discussed by de-Madaria *et al*[11] and information on pancreatic cancer patients, reported by three studies[12-14] is at this point far too scarce to even discuss its relation with COVID-19 and effect on outcomes. There were no other deviations from the protocol.

***Eligibility criteria***

Any study, regardless of design, was considered eligible if it contained the original data on at least 1 SARS-CoV-2-infected individual diagnosed with AP. Only human studies were eligible; studies containing solely animal or *in vitro* data were excluded.

***Systematic search and selection; data extraction***

Using the same search key as detailed in the supplementary material (Supplemental 1), the systematic search was conducted in five databases: Embase, MEDLINE (*via* PubMed), CENTRAL, Web of Science, and Scopus. The last systematic search was carried out on 14 May 2020. The search was restricted to 2020, and no other filters were applied. Citations were exported to a reference management program (EndNote X9, Clarivate Analytics). Two independent review authors (Ocskay K and Juhász MF) conducted the selection by title, abstract and full text based on the previously disclosed, predetermined set of rules. After each selection step, Cohen’s kappa coefficient (κ)[15] was calculated. An independent third party (SK) settled any disagreements. Citing articles and references in the studies assessed for eligibility in the full-text phase were reviewed to identify any additional eligible records. Data were extracted from all eligible studies into a standardized Excel sheet designed on the basis of recommendations from the Cochrane Collaboration[16] (for details on data extraction, see Supplemental 2).

***Risk of bias assessment and determination of the quality of evidence***

The Joanna Briggs Institute Critical Appraisal Checklist for Case Reports[17] was used to assess the risk of bias in case reports, and the Newcastle–Ottawa Scale[18] was used for cohorts (results in Supplemental 3). Due to the design and quality of the included studies, the Grading of Recommendations, Assessment, Development, and Evaluations approach was not used and a very low grade of evidence was automatically established.

***Statistical analysis***

Only qualitative synthesis was performed; no statistical analysis was carried out.

**RESULTS**

***Systematic search and selection***

The details of the systematic search and selection are presented in Figure 1.

***Characteristics of included studies***

In total, six case reports and two retrospective cohort studies were included in this systematic review (Table 1). Information on the diagnostic criteria and etiological factors of AP was collected from the appropriate case reports in Table 2. Of the six cases, five fulfilled the diagnostic criteria for acute pancreatitis[19], and in one case[20] enzyme elevation reached the threshold. However, abdominal pain could not be reported on account of the patient being ventilated and sedated, and no imaging findings were disclosed. A case report by Gou *et al*[21] was not included in this table, as biliary etiology was determined and COVID-19 symptoms first emerged on day 18 of the patient’s hospital stay; thus, the infection was not assumed as an etiological factor[21].

In a retrospective cohort of COVID-19 mortality cases by Li *et al*[22], AP is listed as an underlying disease in a single patient without further clarification as to whether it is a past event from the patient’s medical history or it occurred during COVID-19-related hospitalization[22]. Hossain *et al*[23] noted three cases of AP among 119 patients presenting to the ER with non-respiratory symptoms who turned out to have concomitant SARS-CoV-2 infection[23].

**DISCUSSION**

The multiple-hit theory can be implemented in the pathogenesis of AP[24]; therefore, information on possible contributing factors was collected for each case (Table 2). Multiple etiological factors are often responsible for AP[24], but the lack of proper workup often leads to cases being deemed idiopathic or an important factor not being discovered due to the presence of a more convenient diagnosis[6]. In addition to the established etiological factors, various mechanisms have been postulated as the cause of pancreatic damage in COVID-19.

SARS-CoV-2 enters epithelia through the angiotensin-converting enzyme 2[25], which is abundantly expressed in the pancreas[26,27]. SARS-CoV-2 RNA and protein were also shown by *in situ* hybridization and immunohistochemistry from autopsy samples of infected patients’ pancreas[28]. Aloysius proposed that virus replication may have a direct cytopathic effect or elicit pancreatic cell death as a consequence of the immune response[29]. Furthermore, microvascular injury and thrombosis have been described as a consequence of COVID-19[30,31], which, complicated with shock and gastrointestinal hypoperfusion[32], could also cause pancreatic damage[33].

However, a cause-effect relationship has not been investigated directly so far. Also, before entertaining the possibility of a new virus as a causative agent in cases where no apparent etiological factors are present, other, less frequent causes of AP must be considered. In such cases, the International Association of Pancreatology/American Pancreatic Association (IAP/APA) recommendations should be followed[6,7,19].

For instance, drugs used in treating COVID-19 may cause pancreatic damage directly or indirectly. A patient whose case was presented as idiopathic AP was on a course of doxycycline, which is a drug with a documented probable association with pancreatitis[34]. Several drugs currently used or being considered for COVID-19 might play a role in the pathogenesis of pancreatitis, such as enalapril, asparaginase, estrogens, and steroids[34]. Hypertriglyceridemia, another established etiological factor frequently neglected, can also occur as a consequence of therapy, as in the case described by Morrison *et al*[20]. Not only tocilizumab[35] but propofol and ritonavir could also have been responsible for the elevation of serum triglyceride levels in this case[36]. Hypertriglyceridemia-associated drug-induced AP was observed[37,38] in association with the following drugs being tested for COVID-19 according to our search on clinicaltrials.gov: lisinopril, asparaginase, estrogens, isotretinoin, steroids, propofol, and ruxolitinib.

In a case reported by Aloysius *et al*[29], there are no apparent etiological factors present in the description. Even so, the report does not describe any further efforts to identify the seemingly idiopathic etiology, such as performing an endoscopic ultrasonogram. While thoroughly ruled out AP-associated viruses and even screened for antinuclear antibodies, they also did not utilize endoscopic ultrasonogram during the etiology search.

Other than the highlighted problems tied to the etiological workup, we would like to briefly address an issue with the diagnosis. Two studies not included in this review[9,10] labeled patients with serum amylase and/or lipase values higher than the upper limit of normal to possess “pancreatic injury”. As de-Madaria *et al*[11] pointed out in reflecting on Wang *et al*[9], the elevation of pancreatic enzyme levels in the blood is not necessarily a consequence of an insult to the pancreas. Possible reasons are the high prevalence of renal impairment and diabetes mellitus, gastroenteritis, and metabolic changes, such as acidosis, or even salivary glandular entry by SARS CoV-2[39-42]. More importantly, a slight elevation in serum amylase and/or lipase levels alone is not established as an indicator of pancreatic damage. The Atlanta diagnostic criteria should be applied when determining the presence of AP[19].

The case reports in our review carry considerable risk of bias and their deviation from the Case Report guideline[43] on reporting methods. As demonstrated, the etiological workup of patients was incomplete, and often COVID-19 was named as the causative agent of AP, while other established factors were also present.

Considering limitations, incomplete reporting of the included studies encompasses a high risk of bias in our analysis[44-46].

**CONCLUSION**

To conclude, we strongly emphasize the need for guideline adherence when diagnosing and uncovering the underlying etiological factors of AP, even during a pandemic. As specific therapeutic options[19] are available depending on etiology, neglecting these steps can hinder direct therapy and lower the chances of recovery, while increasing the probability of complications and recurrent episodes.

**ARTICLE HIGHLIGHTS**

***Research background***

Since the rapid progression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, numerous publications postulated pancreatic involvement. Furthermore, angiotensin-converting enzyme 2 expression -the cellular entry point of the virus- was described in the pancreas.

***Research motivation***

Multiple etiological factors can be uncovered in a large proportion of acute pancreatitis cases. Therefore, the characterization of SARS-CoV-2 infection as a potential contributing factor was necessary.

***Research objectives***

Our aim was to review all available clinical evidence on acute pancreatitis cases in coronavirus disease 2019 (COVID-19) patients and to analyze the role of COVID-19 as an etiological factor.

***Research methods***

A systematic search was conducted in five databases on 14 May 2020 (registration number CRD42020186426). Record selection and data extraction were carried out by two independent review authors. Studies containing the original data of at least 1 SARS-CoV-2-infected individual diagnosed with acute pancreatitis were considered eligible. The Joanna Briggs Institute Critical Appraisal Checklist for Case Reports and the Newcastle–Ottawa Scale were used for risk of bias assessment.

***Research results***

Eight studies (six case reports and two retrospective cohort studies) were included in this systematic review. All acute pancreatitis cases lacked proper etiological workup, but SARS-CoV-2 infection was confirmed by polymerase chain reaction in all cases. High risk of bias and non-compliance with the Case Report guideline was noted in all case reports.

***Research conclusions***

Guideline adherence is a quality indicator of patient care. We advise all clinicians to conduct proper etiological workup before entertaining the possibility of SARS-CoV-2 as a causative agent of acute pancreatitis.

***Research perspectives***

The potential mechanisms of pancreatic damage in COVID-19 should be investigated utilizing basic research methods and animal models to evaluate a possible causative association between SARS-CoV-2 and AP.

**REFERENCES**

1 **Li LQ**, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, Sun W, Wang Y. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol* 2020; **92**: 577-583 [PMID: 32162702 DOI: 10.1002/jmv.25757]

2 **Conti P**, Gallenga CE, Tetè G, Caraffa A, Ronconi G, Younes A, Toniato E, Ross R, Kritas SK. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. *J Biol Regul Homeost Agents* 2020; **34**: 333-338 [PMID: 32228825 DOI: 10.23812/Editorial-Conti-2]

3 **Tian Y**, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. *Aliment Pharmacol Ther* 2020; **51**: 843-851 [PMID: 32222988 DOI: 10.1111/apt.15731]

4 **Xiao F**, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. *Gastroenterology* 2020; **158**: 1831-1833.e3 [PMID: 32142773 DOI: 10.1053/j.gastro.2020.02.055]

5 **Rawla P**, Bandaru SS, Vellipuram AR. Review of Infectious Etiology of Acute Pancreatitis. *Gastroenterology Res* 2017; **10**: 153-158 [PMID: 28725301 DOI: 10.14740/gr858w]

6 **Zádori N**, Párniczky A, Szentesi A, Hegyi P. Insufficient implementation of the IAP/APA guidelines on aetiology in acute pancreatitis: Is there a need for implementation managers in pancreatology? *United European Gastroenterol J* 2020; **8**: 246-248 [PMID: 32310740 DOI: 10.1177/2050640620918695]

7 **Hallensleben ND**, Umans DS, Bouwense SA, Verdonk RC, Romkens TE, Witteman BJ, Schwartz MP, Spanier MB, Laheij R, van Santvoort HC, Besselink MG, van Hooft JE, Bruno MJ; Dutch Pancreatitis Study Group. The diagnostic work-up and outcomes of 'presumed' idiopathic acute pancreatitis: A post-hoc analysis of a multicentre observational cohort. *United European Gastroenterol J* 2020; **8**: 340-350 [PMID: 32213015 DOI: 10.1177/2050640619890462]

8 **Mosztbacher D**, Hanák L, Farkas N, Szentesi A, Mikó A, Bajor J, Sarlós P, Czimmer J, Vincze Á, Hegyi PJ, ErÅ‘ss B, Takács T, Czakó L, Németh BC, Izbéki F, Halász A, Gajdán L, Hamvas J, Papp M, Földi I, Fehér KE, Varga M, Csefkó K, Török I, Farkas HP, Mickevicius A, Maldonado ER, Sallinen V, Novák J, Ince AT, Galeev S, Bod B, Sümegi J, Pencik P, Dubravcsik Z, Illés D, Gódi S, Kui B, Márta K, Pécsi D, Varjú P, Szakács Z, Darvasi E, Párniczky A, Hegyi P; Hungarian Pancreatic Study Group. Hypertriglyceridemia-induced acute pancreatitis: A prospective, multicenter, international cohort analysis of 716 acute pancreatitis cases. *Pancreatology* 2020; **20**: 608-616 [PMID: 32402696 DOI: 10.1016/j.pan.2020.03.018]

9 **Wang F**, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia. *Gastroenterology* 2020; **159**: 367-370 [PMID: 32247022 DOI: 10.1053/j.gastro.2020.03.055]

10 **Liu F**, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. *Clin Gastroenterol Hepatol* 2020; **18**: 2128-2130.e2 [PMID: 32334082 DOI: 10.1016/j.cgh.2020.04.040]

11 **de-Madaria E**, Siau K, Cárdenas-Jaén K. Increased amylase and lipase in patients with COVID-19 pneumonia: don´t blame the pancreas just yet! *Gastroenterology* 2020 [PMID: 32330475 DOI: 10.1053/j.gastro.2020.04.044]

12 **Dane B**, Brusca-Augello G, Kim D, Katz DS. Unexpected Findings of Coronavirus Disease (COVID-19) at the Lung Bases on Abdominopelvic CT. *AJR Am J Roentgenol* 2020; **215**: 603-606 [PMID: 32319792 DOI: 10.2214/AJR.20.23240]

13 **Luong-Nguyen M**, Hermand H, Abdalla S, Cabrit N, Hobeika C, Brouquet A, Goéré D, Sauvanet A. Nosocomial infection with SARS-Cov-2 within Departments of Digestive Surgery. *J Visc Surg* 2020; **157**: S13-S18 [PMID: 32381426 DOI: 10.1016/j.jviscsurg.2020.04.016]

14 **Yu J**, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. *JAMA Oncol* 2020; **6**: 1108-1110 [PMID: 32211820 DOI: 10.1001/jamaoncol.2020.0980]

15 **McHugh ML**. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)* 2012; **22**: 276-282 [PMID: 23092060]

16 **Li T,** Higgins JPT, Deeks JJ. Chapter 5 Collecting data. Cochrane Handbook for Systematic Reviews of Interventions. 2019: 109-141

17 **Moola S**, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Lisy K, Qureshi R, Mattis P, Mu P. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from: URL: https://synthesismanual.jbi.global. https://doi.org/10.46658/JBIMES-20-08

18 **Wells G**, Shea B, O'Connell D, Peterson j, Welch V, Losos M, Tugwell P. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. 2000. Available from: URL: http://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp

19 **Working Group IAP/APA Acute Pancreatitis Guidelines.** IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology* 2013; **13**: e1-15 [PMID: 24054878 DOI: 10.1016/j.pan.2013.07.063]

20 **Morrison AR**, Johnson JM, Ramesh M, Bradley P, Jennings J, Smith ZR. Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab. *J Med Virol* 2020 [PMID: 32314799 DOI: 10.1002/jmv.25907]

21 **Gou SM**, Yin T, Xiong JX, Peng T, Li Y, Wu HS. [Treatment of pancreatic diseases and prevention of infection during outbreak of 2019 coronavirus disease]. *Zhonghua Wai Ke Za Zhi* 2020; **58**: 326-330 [PMID: 32107909 DOI: 10.3760/cma.j.cn112139-20200224-00123]

22 **Li X**, Wang L, Yan S, Yang F, Xiang L, Zhu J, Shen B, Gong Z. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. *Int J Infect Dis* 2020; **94**: 128-132 [PMID: 32251805 DOI: 10.1016/j.ijid.2020.03.053]

23 **Hossain R**, Lazarus MS, Roudenko A, Dako F, Mehta V, Alis J, Zalta B, Lei B, Haramati LB, White CS. CT Scans Obtained for Nonpulmonary Indications: Associated Respiratory Findings of COVID-19. *Radiology* 2020; **296**: E173-E179 [PMID: 32391741 DOI: 10.1148/radiol.2020201743]

24 **Sahin-Tóth M**, Hegyi P. Smoking and Drinking Synergize in Pancreatitis: Multiple Hits on Multiple Targets. *Gastroenterology* 2017; **153**: 1479-1481 [PMID: 29100845 DOI: 10.1053/j.gastro.2017.10.031]

25 **Dalan R**, Bornstein SR, El-Armouche A, Rodionov RN, Markov A, Wielockx B, Beuschlein F, Boehm BO. The ACE-2 in COVID-19: Foe or Friend? *Horm Metab Res* 2020; **52**: 257-263 [PMID: 32340044 DOI: 10.1055/a-1155-0501]

26 **Yang JK**, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. *Acta Diabetol* 2010; **47**: 193-199 [PMID: 19333547 DOI: 10.1007/s00592-009-0109-4]

27 **Fang HJ**, Yang JK. Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas. *J Int Med Res* 2010; **38**: 558-569 [PMID: 20515569 DOI: 10.1177/147323001003800218]

28 **Ding Y**, He L, Zhang Q, Huang Z, Che X, Hou J, Wang H, Shen H, Qiu L, Li Z, Geng J, Cai J, Han H, Li X, Kang W, Weng D, Liang P, Jiang S. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. *J Pathol* 2004; **203**: 622-630 [PMID: 15141376 DOI: 10.1002/path.1560]

29 **Aloysius MM**, Thatti A, Gupta A, Sharma N, Bansal P, Goyal H. COVID-19 presenting as acute pancreatitis. *Pancreatology* 2020; **20**: 1026-1027 [PMID: 32444169 DOI: 10.1016/j.pan.2020.05.003]

30 **Magro C**, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res* 2020; **220**: 1-13 [PMID: 32299776 DOI: 10.1016/j.trsl.2020.04.007]

31 **Yao XH**, Li TY, He ZC, Ping YF, Liu HW, Yu SC, Mou HM, Wang LH, Zhang HR, Fu WJ, Luo T, Liu F, Guo QN, Chen C, Xiao HL, Guo HT, Lin S, Xiang DF, Shi Y, Pan GQ, Li QR, Huang X, Cui Y, Liu XZ, Tang W, Pan PF, Huang XQ, Ding YQ, Bian XW. [A pathological report of three COVID-19 cases by minimal invasive autopsies]. *Zhonghua Bing Li Xue Za Zhi* 2020; **49**: 411-417 [PMID: 32172546 DOI: 10.3760/cma.j.cn112151-20200312-00193]

32 **van Haren FM**, Sleigh JW, Pickkers P, Van der Hoeven JG. Gastrointestinal perfusion in septic shock. *Anaesth Intensive Care* 2007; **35**: 679-694 [PMID: 17933153 DOI: 10.1177/0310057x0703500505]

33 **Hackert T**, Hartwig W, Fritz S, Schneider L, Strobel O, Werner J. Ischemic acute pancreatitis: clinical features of 11 patients and review of the literature. *Am J Surg* 2009; **197**: 450-454 [PMID: 18778810 DOI: 10.1016/j.amjsurg.2008.04.011]

34 **Nitsche C**, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J. Drug-induced pancreatitis. *Curr Gastroenterol Rep* 2012; **14**: 131-138 [PMID: 22314811 DOI: 10.1007/s11894-012-0245-9]

35 **Flaig T**, Douros A, Bronder E, Klimpel A, Kreutz R, Garbe E. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. *J Clin Pharm Ther* 2016; **41**: 718-721 [PMID: 27670839 DOI: 10.1111/jcpt.12456]

36 **Rubel AR**, Chong PL, Abdullah MS, Asli R, Momin RN, Mani BI, Chong VH. Lipemic serum in patients with Coronavirus Disease 2019 (COVID-19) undergoing treatment. *J Med Virol* 2020 [PMID: 32343413 DOI: 10.1002/jmv.25942]

37 **Watson AP**, Brunstein CG, Holtan SG. Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease. *Case Rep Transplant* 2018; **2018**: 4539757 [PMID: 30519495 DOI: 10.1155/2018/4539757]

38 **Elkhouly MA**, Salazar MJ, Simons-Linares CR. Hypertriglyceridemia-Associated Drug-Induced Acute Pancreatitis. *Pancreas* 2019; **48**: 22-35 [PMID: 30531242 DOI: 10.1097/MPA.0000000000001190]

39 **Tositti G**, Fabris P, Barnes E, Furlan F, Franzetti M, Stecca C, Pignattari E, Pesavento V, de Lalla F. Pancreatic hyperamylasemia during acute gastroenteritis: incidence and clinical relevance. *BMC Infect Dis* 2001; **1**: 18 [PMID: 11667952 DOI: 10.1186/1471-2334-1-18]

40 **Steinberg WM**, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB; LEADER Trial investigators. LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. *Pancreas* 2014; **43**: 1223-1231 [PMID: 25275271 DOI: 10.1097/MPA.0000000000000229]

41 **Liu L**, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, Jiang H, Zhou J, Lam P, Zhang L, Lackner A, Qin C, Chen Z. Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. *J Virol* 2011; **85**: 4025-4030 [PMID: 21289121 DOI: 10.1128/JVI.02292-10]

42 **Wang C**, Wu H, Ding X, Ji H, Jiao P, Song H, Li S, Du H. Does infection of 2019 novel coronavirus cause acute and/or chronic sialadenitis? *Med Hypotheses* 2020; **140**: 109789 [PMID: 32361098 DOI: 10.1016/j.mehy.2020.109789]

43 **Riley DS**, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, Kiene H, Helfand M, Altman DG, Sox H, Werthmann PG, Moher D, Rison RA, Shamseer L, Koch CA, Sun GH, Hanaway P, Sudak NL, Kaszkin-Bettag M, Carpenter JE, Gagnier JJ. CARE guidelines for case reports: explanation and elaboration document. *J Clin Epidemiol* 2017; **89**: 218-235 [PMID: 28529185 DOI: 10.1016/j.jclinepi.2017.04.026]

44 **Anand ER**, Major C, Pickering O, Nelson M. Acute pancreatitis in a COVID-19 patient. *Br J Surg* 2020; **107**: e182 [PMID: 32339257 DOI: 10.1002/bjs.11657]

45 **Hadi A**, Werge M, Kristiansen KT, Pedersen UG, Karstensen JG, Novovic S, Gluud LL. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members. *Pancreatology* 2020; **20**: 665-667 [PMID: 32387082 DOI: 10.1016/j.pan.2020.04.021]

46 **Meireles PA**, Bessa F, Gaspar P, Parreira I, Silva VD, Mota C, Alvoeiro L. Acalculous Acute Pancreatitis in a COVID-19 Patient. *Eur J Case Rep Intern Med* 2020; **7**: 001710 [PMID: 32523925 DOI: 10.12890/2020\_001710]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interest.

**PRISMA 2009 Checklist statement:** The guidelines of the PRISMA 2009 statement have been adopted.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding Author's Membership in Professional Societies:** International Association of Pancreatology, No. 4418.

**Peer-review started:** June 17, 2020

**First decision:** July 28, 2020

**Article in press:** September 23, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Hungary

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Tjora E **S-Editor:** Zhang L **L-Editor:A P-Editor:** Ma YJ

**Figure Legends**



**Figure 1 PRISMA flow diagram demonstrating the selection of studies to be included in the review.** K represents Cohen’s Kappa values indicating the rate of agreement between selection coordinators. COVID-19: Coronavirus disease 2019.

**Table 1 Characteristics of included studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Study population** | **AP *n* (%)** | **Description** |
| Aloysius *et al*[29],United States | Case report | One AP patient with COVID-19 | 1 (100) | 36-year-old obese female presenting with AP. No sign of biliary pathology, denies alcoholism, TG unremarkable |
| Anand *et al*[44], United Kingdom | Case report | One AP patient with COVID-19 | 1 (100) | A 59-year-old cholecystectomized woman with minimal alcohol consumption, readmitted with abdominal symptoms five days after discharge with doxycycline for co-infection. CT showed signs of AP on a formerly atrophic pancreas |
| Gou *et al*[21], China | Case report | Four “pancreatic disease” patients with COVID-19 pneumonia | 1 (25) | One female with AP (51), biliary etiology confirmed, showed initial COVID-19 symptoms 18 d after admission |
| Hadi *et al*[45], Denmark | Case report | Three family members with COVID-19 | 2 (67) | Idiopathic AP in mother (68) and daughter (47), both requiring intensive care and ventilation |
| Hossain *et al*[23], United States | Retrospective cohort | 119 COVID-19 patients presenting at ER with non-respiratory symptoms | 3/32 (9.4) | Out of the 101 instances where abdominal/pelvic CT was obtained, 32 had acute/significant findings, including three cases of pancreatitis. No more information available on these patients |
| Li *et al*[22], China | Retrospective cohort | 25 death cases with COVID-19 | 1 (4) | A 56-year-old male patient had AP as an “underlying disease”–it is not clear whether this is from his medical history or was present concomitantly |
| Meireles *et al*[46], Portugal | Case report | One AP patient with COVID-19 | 1 (100) | 36-year-old female, AP symptoms started on day 11 of disease, US and CT showed no signs of biliary pathology/ischemia. No information on alcohol consumption. Negatively screened for multiple viruses |
| Morrison *et al*[20], United States | Case report | Two cases of acute hypertriglyceridemia in COVID-19 patients | 1 (50) | Acute hypertriglyceridemia-induced AP after treatment with tocilizumab, ritonavir, lopinavir, ribavirin, hydroxychloroquine, and propofol |

AP *n* (%) is the number (percentage) of patients with acute pancreatitis. COVID-19: Coronavirus disease 2019; AP: Acute pancreatitis; US: Ultrasonography; CT: Computed tomography.

**Table 2 Diagnostic and etiological workup and quality assessment of the studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Diagnostic workup** | **COVID-19 (PCR)** | **Etiological workup** | **Quality of case reports** |
| **Abdominal pain** | **Enzyme elevation (3 x)** | **Imaging** | **Biliary** | **Alcohol** | **HTG (> 11.5 mmol/L)** | **Drug** | **Hyper-calcemia** | **Ischemia** | **Auto-immunity** | **Viral (except nCoV)** | **Anatomy** | **JBI Overall rating ( /8)** | **Written according to CARE** |
| Aloysius *et al*[29],United States | + | + | - | + | ? | - | - | - | ? | ? | ? | ? | - | 3 | No |
| Anand *et al*[44], United Kingdom | + | ? | + | + | ? | - | ? | + | ? | ? | ? | ? | - | 0 | No |
| Hadi *et al*[45], Denmark | ? | + | + | + | ? | - | - | ? | - | + | ? | ? | ? | 4 | No |
| + | + | ? | + | ? | ? | ? | + | - | + | ? | ? | ? | 2 |
| Meireles *et al*[46], Portugal | + | + | - | + | ? | - | - | - | - | - | - | - | - | 1 | No |
| Morrison *et al*[20], United States | ? | + | ? | + | ? | ? | + | + | ? | + | ? | ? | ? | 1 | No |

The Atlanta criteria were used for diagnosis. Biliary microlithiasis was included in the “biliary” etiology, so endoscopic ultrasonography or magnetic resonance cholangiopancreatography was needed to rule out this factor. Ischemia was considered in the case of shock and vasopressor therapy and was ruled out by computed tomography angiogram. Anatomical malformations were ruled out by computed tomography. The two columns on the right demonstrate the quality of included case reports based on the risk of bias according to the overall Joanna Briggs Institute Critical Appraisal score and adherence to Case Report guidelines on reporting cases. CARE: Case Report Guidelines; JBI: Joanna Briggs Institute; PCR: Polymerase chain reaction.